Unknown

Dataset Information

0

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.


ABSTRACT: We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). In DLBCL, PD-L1 elevation was more frequent in responders versus nonresponders (5/8 [62.5%] vs. 3/16 [18.8%]; p?=?0.065; complete response 37.5% vs. 0%; p?=?0.028). Overall response rates for patients with WES and GEP data, respectively, were: DLBCL (38.5% and 29.6%); FL (46.2% and 43.5%); RT (76.5% and 81.3%). In DLBCL, WES analyses demonstrated that mutations in RNF213 (40.0% vs. 6.2%; p?=?0.055), KLHL14 (30.0% vs. 0%; p?=?0.046), and LRP1B (30.0% vs. 6.2%; p?=?0.264) were more frequent in responders. No responders had mutations in EBF1, ADAMTS20, AKAP9, TP53, MYD88, or TNFRSF14, while the frequency of these mutations in nonresponders ranged from 12.5% to 18.8%. In FL and RT, genes with different mutation frequencies in responders versus nonresponders were: BCL2 (75.0% vs. 28.6%; p?=?0.047) and ROS1 (0% vs. 50.0%; p?=?0.044), respectively. Per GEP, the most upregulated genes in responders were LEF1 and BTLA (overall), and CRTAM (germinal center B-cell-like DLBCL). Enriched pathways were related to immune activation in responders and resistance-associated proliferation/replication in nonresponders. This preliminary work may help to generate hypotheses regarding genetically defined subsets of DLBCL, FL, and RT patients most likely to benefit from ibrutinib plus nivolumab.

SUBMITTER: Hodkinson BP 

PROVIDER: S-EPMC7723809 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.

Hodkinson Brendan P BP   Schaffer Michael M   Brody Joshua D JD   Jurczak Wojciech W   Carpio Cecilia C   Ben-Yehuda Dina D   Avivi Irit I   Forslund Ann A   Özcan Muhit M   Alvarez John J   Ceulemans Rob R   Fourneau Nele N   Younes Anas A   Balasubramanian Sriram S  

Translational oncology 20201206 1


We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). In DLBCL, PD-L1 elevation was more frequent in responders versus nonresponders (5/8 [62.5%] vs. 3/16 [18.8%]; p = 0.065; complete re  ...[more]

Similar Datasets

| S-EPMC6904508 | biostudies-literature
| S-EPMC6388933 | biostudies-literature
| S-EPMC3301422 | biostudies-other
| S-EPMC5757691 | biostudies-literature
| S-EPMC8759132 | biostudies-literature
| S-EPMC7244150 | biostudies-literature
| S-EPMC8751801 | biostudies-literature
| S-EPMC9631700 | biostudies-literature
| S-EPMC2532951 | biostudies-literature
| S-EPMC10000669 | biostudies-literature